Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo attack on rare blood cancer shows promise in early trial

NCT ID NCT07502768

Recruiting now Disease control Sponsor: Rong Tao Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, not cure it, and participants will need ongoing monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRANODAL NK/T-CELL LYMPHOMA NK/T-CELL LYMPHOMA RELAPSED OR REFRACTORY NK/T-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200043, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••